Tumor lysis syndrome primary prevention

Jump to navigation Jump to search

Tumor lysis syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tumor lysis syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tumor lysis syndrome primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tumor lysis syndrome primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tumor lysis syndrome primary prevention

CDC on Tumor lysis syndrome primary prevention

Tumor lysis syndrome primary prevention in the news

Blogs on Tumor lysis syndrome primary prevention

Directions to Hospitals Treating Tumor lysis syndrome

Risk calculators and risk factors for Tumor lysis syndrome primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]

Overview

Effective measures for the primary prevention of tumor lysis syndrome include allopurinol, rasburicase, and intravenous hydration.

Prevention

Before initiating chemotherapy for cancer patients, especially lymphomas and leukemias, patients should receive the following:[1]

Patient population Treatment

Low risk

  • Adequate intravenous hydration to maintain a high urine output (> 2.5 L/day)
  • Alkalinization of urine is not recommended.[2]

Intermediate risk

  • Adults dosing: 200-400mg/m2/day in 1-3 divided doses; maximum dose is 800mg/day
  • Infants weighing less than 10kg: 3.3mg/kg every 8 hours

High risk

  • 0.2mg/kg for 5-7 days
  • A single dose of 3 mg may be used in high risk patients
  • Contraindicated in patients with glucose 6 phosphate dehydrogenase (G6PD) deficiency

References

  1. Jones, Gail L; Will, Andrew; Jackson, Graham H; Webb, Nicholas J A; Rule, Simon (2015). "Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology". British Journal of Haematology. 169 (5): 661–671. doi:10.1111/bjh.13403. ISSN 0007-1048.
  2. Ten Harkel AD, Kist-Van Holthe JE, Van Weel M, Van der Vorst MM (1998). "Alkalinization and the tumor lysis syndrome". Med Pediatr Oncol. 31 (1): 27–8. PMID 9607427.

Template:WH Template:WS